Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 8/20 | 0.61 |
| ▸ | TOP2B | Q02880 | 8/20 | 0.61 |
| ▸ | MMP2 | P08253 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | MITF | O75030 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | RAD52 | P43351 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8104150 | 0.89 | TOP2A (0.60) | TOP2ATOP2BMMP2KDM4EMAPT | |
| SCHEMBL3980219 | 0.87 | TOP2A (0.60) | TOP2ATOP2BKMT2AMEN1HDAC8 | |
| SCHEMBL3984348 | 0.85 | TOP2A (0.64) | TOP2ATOP2BKDM4EMAPTKMT2A | |
| SCHEMBL8104139 | 0.83 | TOP2A (0.60) | TOP2ATOP2BKDM4EMAPTKMT2A | |
| SCHEMBL5404447 | 0.81 | TOP2A (0.66) | TOP2ATOP2BKDM4EMAPTKMT2A | |
| SCHEMBL3989825 | 0.81 | TOP2A (0.66) | TOP2ATOP2BKDM4EMAPTKMT2A | |
| SCHEMBL9299772 | 0.80 | TOP2A (0.62) | TOP2ATOP2BKDM4EMAPTKMT2A | |
| SCHEMBL3984667 | 0.79 | TOP2A (0.64) | TOP2ATOP2BKDM4EMAPTKMT2A | |
| SCHEMBL9300052 | 0.79 | TOP2A (0.73) | TOP2ATOP2BKDM4EMAPTKMT2A | |
| SCHEMBL3986033 | 0.78 | TOP2A (0.60) | TOP2ATOP2BKMT2AMEN1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1380574-A1 | 9-aminoacridine derivates and process for the preparation thereof | Samjin Pharmaceutical Co., Ltd. (KR) | 2004-01-14 | — | — | EP | disclosed |
| US-6620936-B2 | Antitumor agents, topoisomerase inhibitors, notoxic | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2003-09-16 | — | — | US | disclosed |
| US-20020111491-A1 | 9-aminoacridine derivatives and process for the preparation thereof | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2002-08-15 | — | — | US | disclosed |
| EP-1062207-A1 | 9-AMINOACRIDINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | Samjin Pharmaceutical Co., Ltd. (KR) | 2000-12-27 | — | — | EP | disclosed |
| WO-2000037447-A1 | 9-AMINOACRIDINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2000-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111491-A1 | 9-aminoacridine derivatives and process for the preparation thereof | ALKBH1, ADCY9, CCR9 | TOP2A 1105/4885TOP2B 841/4885MMP2 2002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.